Spindletop Health Acquisition Corp.
Status: Liquidated
U=S+W/2
W=S@11.5
IPO Proceeds, $M | $230.00M |
---|---|
IPO Date | Nov 4, 2021 |
CEO | Evan S. Melrose, M.D., MBA |
Left Lead | Barclays |
IPO Cash in Trust | 102.0% |
SPAC Tenor | 15 + (3) or 15 + (2*3) |
IPO Sector |
Healthcare
Healthcare services, healthcare information technology, insurance and related products, biotechnology, pharmaceuticals, medical devices, and diagnostics |
IPO Geography | Global |
Target Company | N/A |
Deal Announced | N/A |
Deal Size, $M | TBD |
Deal Sector | TBD |
Deal Geography | TBD |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | Dec 20, 2022 |
Closing Date | Dec 20, 2022 |
SHCA
SHCAU
SHCAW
Price | |
---|---|
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Price | |
---|---|
Volume, today | |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Spindletop Health Acquisition Corp.:
- Structure and cap table
- 8 directors & officers
- 12 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Evan S. Melrose, M.D., MBA | 51 | Chief Executive Officer, Chief Financial Officer and Director |
James H. Henry, CPA | 63 | Chairman of the Board of Directors |
Steve Whitlock, MBA | 59 | Secretary |
JD Moore, MBA | 48 | Senior Vice President, Corporate Development |
Kelly Huang, Ph.D. | 52 | Chief Operating Officer |
Craig Cordola, MBA | 49 | Director |
Todd Fruchterman, M.D., Ph.D. | 51 | Director |
David Nash, M.D., MBA | 65 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Barclays | Joint BR | 13,000,000 | units |
Stifel Nicolaus | Joint BR | 7,000,000 | |
20,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee | 3.50 | % |
Sign in to view more advisor data.
Filings
Sign in to view 12 filings.